Article citationsMore>>

Herbst, R.S., Majem, M., Barlesi, F., et al. (2022) COAST: An Open-Label, Phase, I.I., Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, Article ID: JCO2200227. Epub Ahead of Print.
https://doi.org/10.1200/JCO.22.00227

has been cited by the following article:

• TITLE: Immunotherapy in Early Stage Non-Small Cell Lung Cancer

  AUTHORS: Jeyanthi Ramanarayanan, Ganapathy Krishnan

  KEYWORDS: Non-Small Cell Lung Cancer, Immunotherapy, Immune Checkpoint Inhibitors, Adjuvant, Neoadjuvant, Early Stage

  JOURNAL NAME: Advances in Lung Cancer, Vol.11 No.3, September 1, 2022

  ABSTRACT: Immune-checkpoint inhibitors are extensively used in cancer treatment and have transformed the therapeutic landscape by inducing durable responses. Immunotherapy with checkpoint inhibitors targeting programmed death 1 (PD-1) receptor and programmed death ligand-1 (PDL-1) are used alone or with chemotherapy for treatment of metastatic non-small cell lung cancer (NSCLC). There is a great need for improving outcomes of patients with early stage NSCLC after surgical resection and with recent F. D. A. approval, immune checkpoint inhibitors are used as neoadjuvant or adjuvant therapy to enable curative resection and prevent or delay disease progression. In this article, we review the clinical studies evaluating the role of adjuvant and neoadjuvant immune checkpoint inhibitors in NSCLC and discuss the role of immunotherapy with radiation therapy in locally advanced non-metastatic NSCLC.